These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20645167)

  • 1. Different methods for testing potential cyclooxygenase-1 and cyclooxygenase-2 inhibitors.
    Laufer S; Luik S
    Methods Mol Biol; 2010; 644():91-116. PubMed ID: 20645167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro assays for cyclooxygenase activity and inhibitor characterization.
    Walker MC; Gierse JK
    Methods Mol Biol; 2010; 644():131-44. PubMed ID: 20645170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.
    Gray PA; Warner TD; Vojnovic I; Del Soldato P; Parikh A; Scadding GK; Mitchell JA
    Br J Pharmacol; 2002 Dec; 137(7):1031-8. PubMed ID: 12429575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events.
    Mitchell JA; Lucas R; Vojnovic I; Hasan K; Pepper JR; Warner TD
    FASEB J; 2006 Dec; 20(14):2468-75. PubMed ID: 17142796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of both COX-1 and COX-2 and resulting decrease in the level of prostaglandins E2 is responsible for non-steroidal anti-inflammatory drug (NSAID)-dependent exacerbation of colitis.
    Tanaka K; Suemasu S; Ishihara T; Tasaka Y; Arai Y; Mizushima T
    Eur J Pharmacol; 2009 Jan; 603(1-3):120-32. PubMed ID: 19101538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
    Hayashi S; Sumi Y; Ueno N; Murase A; Takada J
    Biochem Pharmacol; 2011 Oct; 82(7):755-68. PubMed ID: 21741371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation.
    Kirchner T; Argentieri DC; Barbone AG; Singer M; Steber M; Ansell J; Beers SA; Wachter MP; Wu W; Malloy E; Stewart A; Ritchie DM
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1094-101. PubMed ID: 9262379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
    Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
    Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood.
    de Leval X; Delarge J; Devel P; Neven P; Michaux C; Masereel B; Pirotte B; David JL; Henrotin Y; Dogne JM
    Prostaglandins Leukot Essent Fatty Acids; 2001; 64(4-5):211-6. PubMed ID: 11418014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human whole blood assay for rapid and routine testing of non-steroidal anti-inflammatory drugs (NSAIDs) on cyclo-oxygenase-2 activity.
    Laufer S; Greim C; Luik S; Ayoub SS; Dehner F
    Inflammopharmacology; 2008 Aug; 16(4):155-61. PubMed ID: 18759073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.
    Di Nunno L; Vitale P; Scilimati A; Tacconelli S; Patrignani P
    J Med Chem; 2004 Sep; 47(20):4881-90. PubMed ID: 15369392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y; Connor DT; Sercel AD; Sorenson RJ; Doubleday R; Unangst PC; Roth BD; Beylin VG; Gilbertsen RB; Chan K; Schrier DJ; Guglietta A; Bornemeier DA; Dyer RD
    J Med Chem; 1999 Apr; 42(7):1161-9. PubMed ID: 10197960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
    Mitchell JA; Warner TD
    Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and ex vivo inhibition of COX isoforms by robenacoxib in the cat: a comparative study.
    Schmid VB; Seewald W; Lees P; King JN
    J Vet Pharmacol Ther; 2010 Oct; 33(5):444-52. PubMed ID: 20840388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
    King JN; Dawson J; Esser RE; Fujimoto R; Kimble EF; Maniara W; Marshall PJ; O'Byrne L; Quadros E; Toutain PL; Lees P
    J Vet Pharmacol Ther; 2009 Feb; 32(1):1-17. PubMed ID: 19161451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
    Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
    Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.